MST1R and pancreatic ductal adenocarcinoma: Moreover, RON overexpression can increase gemcitabine resistance in pancreatic cancer, and RON inhibition sensitizes pancreatic ductal adenocarcinoma (PDAC) cells to gemcitabine (20).